Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Levels of biomarkers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,169 result(s) found for: Levels of biomarkers. Displaying page 10 of 59.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    EudraCT Number: 2017-002724-25 Sponsor Protocol Number: 08-2018-07-31 Start Date*: 2017-11-16
    Sponsor Name:Helle Holst
    Full Title: Intravenous and oral paracetamol in neonates: safety and ethanol-drug interactions – the PARASHUTE Trial
    Medical condition: Liver toxicity following prolonged administration of i.v. or oral paracetamol
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10019850 Hepatotoxic effect LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003135-35 Sponsor Protocol Number: ECU-aHUS-403 Start Date*: 2016-06-20
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENT
    Medical condition: atypical Hemolytic-Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001910-88 Sponsor Protocol Number: ATYR1940-C-004 Start Date*: 2015-12-17
    Sponsor Name:aTyr Pharma, Inc.
    Full Title: An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Musc...
    Medical condition: Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-001635-91 Sponsor Protocol Number: ODX-MM-001 Start Date*: 2022-08-10
    Sponsor Name:DexTech Medical AB
    Full Title: A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002219-26 Sponsor Protocol Number: RA1100849 Start Date*: 2005-09-08
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react...
    Medical condition: Rheumatoid arthritis (RA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) DE (Completed) DK (Prematurely Ended) ES (Completed) GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002722-22 Sponsor Protocol Number: H2020/755094/2017/IT-01 Start Date*: 2019-06-03
    Sponsor Name:Humanitas Mirasole SpA
    Full Title: Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000685-39 Sponsor Protocol Number: NN9931-4296 Start Date*: 2016-10-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomised, double-blind, ...
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) GR (Completed) BG (Completed) FI (Completed) SE (Completed) NL (Completed) AT (Completed) BE (Completed) FR (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001453-10 Sponsor Protocol Number: BA41510 Start Date*: 2019-09-16
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, LOW-INTERVENTIONAL STUDY DOCUMENTING THE EFFICACY, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY OF STANDARD-OF-CARE TREATMENT WITH ECULIZUMAB OR TREATMENT WITH RAVULIZUMAB IN PATIENTS ...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) that is treated with either eculizumab or ravulizumab as per local label
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004827-36 Sponsor Protocol Number: MOT-C-203 Start Date*: 2019-08-07
    Sponsor Name:INOTREM S.A.
    Full Title: Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study.
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Ongoing) DK (Completed) FI (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000215-89 Sponsor Protocol Number: CL2-16257-099 Start Date*: 2013-06-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, d...
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017242-30 Sponsor Protocol Number: D5132C00001 Start Date*: 2010-12-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Sali...
    Medical condition: Myocardial Infarction, Cardiovascular Death, Atherothombosis, Stroke
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) HU (Completed) RO (Completed) CZ (Completed) SK (Completed) PL (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) NO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002795-13 Sponsor Protocol Number: TACRO-Omics Start Date*: 2020-04-23
    Sponsor Name:Fundación de Investigación Hospital Universitario La Paz
    Full Title: Identification of "omic" biomarkers and their inter and intra-individual variability that allow improvement in the individualization of tacrolimus: uncontrolled clinical trial in pediatric patients...
    Medical condition: Pediatric patients with renal transplantation (under stable treatment with tacrolimus as immunosuppressant)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002672-12 Sponsor Protocol Number: 73807 Start Date*: 2020-12-11
    Sponsor Name:Erasmus Medical Center
    Full Title: Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects
    Medical condition: Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001106-26 Sponsor Protocol Number: EC11-444-OSTEOSARC Start Date*: 2012-07-02
    Sponsor Name:JAVIER MARTÍN BROTO
    Full Title: PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA
    Medical condition: Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004194-40 Sponsor Protocol Number: MYOCARDIAL-IRON Start Date*: 2017-02-07
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Changes in Myocardial Iron Content Following Administration of Intravenous Iron
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001319-71 Sponsor Protocol Number: F1K-MC-EVBQ Start Date*: 2004-08-13
    Sponsor Name:Lilly S.A.
    Full Title: A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96-Hour Infusion With Comm...
    Medical condition: in severe sepsis patients with persistent vasopressordependent hypotension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004370-96 Sponsor Protocol Number: LG-TCS-AD Start Date*: 2019-02-15
    Sponsor Name:Jacob Pontoppidan Thyssen
    Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002476-14 Sponsor Protocol Number: MicrobioTac_MPA Start Date*: 2020-08-20
    Sponsor Name:Oslo University Hospital - Rikshospitalet
    Full Title: IMMUNOSUPPRESSIVE DRUGS AND GUT MICROBIOME: PHARMACOKINETIC- AND MICROBIOME DIVERSITY EFFECTS
    Medical condition: Kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001615-74 Sponsor Protocol Number: ALXN1820-SCD-201 Start Date*: 2023-05-23
    Sponsor Name:Alexion Pharmaceuticals, Inc
    Full Title: A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients with Sickle Cell Disease
    Medical condition: Sickle Cell Disease (HbSS and HBSß thalassemia).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000560-28 Sponsor Protocol Number: ImmunoPeCa Start Date*: 2014-07-24
    Sponsor Name:Oslo University Hospital
    Full Title: PHASE I/II TRIAL OF MOC31PE IMMUNOTOXIN IN PERITONEAL CARCINOMATOSIS FROM COLORECTAL CARCINOMA.
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 14:05:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA